Результаты поиска

Case report: multiple myeloma--a rare presentation.

An unusual case of multiple myeloma is reported in a 61-year-old man presenting with hepatomegaly and multiple hypoechoic lesions in the liver seen on ultrasound. Following cytotoxic chemotherapy the size and number of the lesions within the liver had significantly reduced.

Myeloablative therapy for primary resistant multiple myeloma.

Myeloablative therapy supported by autologous bone marrow or blood stem cell transplantation was assessed in 41 patients who had multiple myeloma resistant to vincristine-doxorubicin by continuous infusion with high-dose dexamethasone (VAD) or other high-dose dexamethasone regimens. In patients who had high or intermediate tumor mass, the myeloma cell mass was reduced by more than 75% in 56% of patients and the survival time quadrupled in comparison with that of a matched control group. Later treatment resulted in a lower response rate and shorter remission. Current myeloablative regimens supp…

Burkitt type leukaemia associated with multiple myeloma.

We describe a 77-year-old man with multiple myeloma (MM) who developed Burkitt type leukaemia (BTL) 16 months after the initial diagnosis of MM. MM was positive for CD10 with immunoglobulin (Ig) kappa, kappa Bence Jones protein (BJP) and a normal karyotype. BTL was positive for CD10, CD19, CD20 and HLA-DR with Ig mu and lambda, lambda BJP and a clonal abnormal karyotype of 46,XY,-13, t(8;14)(q24;q32),11q+,14q+, +mar. The patient died 9 d after diagnosis of BTL despite treatment with multiple agents. This is, to our knowledge, the first such case to be reported.

Peripheral blood B lymphocytes in multiple myeloma.

Multiple myeloma (MM) is a disease of terminally differentiated B lineage cells and thus alterations in circulating B cells may be anticipated. We studied peripheral blood B cells by flow cytometry in 45 untreated MM patients and compared the results to 25 age-matched controls. The total lymphocyte count and the absolute number and percentage of CD20+ cells were significantly decreased in MM patients. Analysis of the relative amounts of CD20+ cells expressing surface immunoglobulin kappa or lambda light chain isotype did not show either clonal B cell excess or light chain isotype suppression. …

Multiple myeloma associated with autoimmune hemolytic anemia.

A rare case of multiple myeloma associated with severe Coombs-positive hemolytic anemia is described. A 60-year-old woman was hospitalized for acute hemolysis due to an IgG warm autoantibody with pan-agglutinin specificity. Serum and urine electrophoresis revealed the presence of a monoclonal IgGk protein and a BJk protein, respectively. Bone marrow aspirates showed diffuse infiltration with plasma cells, and skeletal survey revealed lytic lesions in the skull and diffuse osteoporosis. Treatment with prednisone, and subsequently with melphalan, cyclophosphamide and vincristine resulted in hema…

Adult Fanconi syndrome progressing to multiple myeloma.

A case of adult Fanconi syndrome is described in which there was urinary excretion of kappa light chains. After 13 years the patient developed overt myeloma. She also developed an adenocarcinoma of the colon and an adenocarcinoma of the parathyroid gland. These findings are discussed in relation to the known association between adult Fanconi syndrome, renal damage, and myeloma.

Multiple myeloma presenting as recurrent obstructive uropathy.

A 51-year-old patient who presented with a four-day history of abdominal pain was found to have unilateral ureteral obstruction and an intracalyceal radiolucent filling defect on radiological studies. Further investigation of this was refused by the patient but then years later a repeat intravenous pyelogram showed persistence of the initial intracalyceal filling defect and ureteral obstruction in the contralateral kidney along with multiple intracalyceal radiolucent filling defects. Subsequent investigation led to a diagnosis of kappa light chain myeloma. The diagnosis of multiple myeloma sho…

IgD multiple myeloma. Review of 133 cases.

One hundred thirty-three patients had IgD myeloma. The IgD comprises 0.8% of M-components in general and 2.1% of myelomas in particular. Males predominate and 65% of the patients are younger than 60 years at the diagnosis. More than half of the patients have lymphadenopathy, hepatomegaly, or splenomegaly. Extraosseous spread and amyloidosis are frequent. Severe anemia and azotemia are common. Total serum protein and IgD M-component levels are usually not high. LAMBDA-type light chains are found in 90% of IgD M-components. Bence Jones proteinimia is frequent and Bence Jones proteinuria appears

Стратегии лечения множественной миеломы, основанные на наномедицине.

Множественная миелома (ММ) принадлежит к гематологическим маньякам, и общее число случаев заболевания MM растет во всем мире. В течение последних нескольких десятилетий повышенное внимание уделялось развитию и патогенезу MM. Существенные изменения произошли также в парадигме лечения MM, включая протеаозные ингибиторы, иммуномодуляторы и анти CD38 моноклонные антитела, которые значительно улучшили выживание пациентов. Уделение все большего внимания наномедицине обусловлено ее способностью улучшить лечение MM за счет уменьшения системных побочных эффектов и создания возможностей для более точног…

Secondary neoplasms following treatment for multiple myeloma.

Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of plasma cells within the bone marrow, leading to significant end-organ damage. Recent therapeutic advancements, including immunomodulatory drugs (IMiDs), proteasome inhibitors, autologous stem cell transplant (ASCT), and chimeric antigen receptor T-cell (CAR-T) therapy, have significantly improved survival outcomes. However, with prolonged survival, there is an emerging concern regarding therapy-related secondary malignancies (SM), particularly therapy-related myeloid neoplasms (tMN) and secondary lym…

Daratumumab-EPOCH для преобразованной анапластической множественной миеломы.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… It can debut as the first symptom of multiple myeloma (primary anaplastic myeloma) or transform from an existing myeloma. Anaplastic transformation of multiple myeloma is typically associated with a survival of only a few months [ 1 , 2 ]. … Table 1 Baseline patient and disease features at multiple myeloma diagnosis. …

Exploring health disparities in diagnosing multiple myeloma.

BACKGROUND: Multiple myeloma (MM) is a plasma cell neoplasm, which accounts for 1-2% of cancers and approximately 17% of hematological malignancies in the United States each year. Fifty percent of patients with symptomatic MM have three or more primary care visits before being referred to a specialist, which is greater than any other cancer. A delay in the diagnosis of multiple myeloma has been shown to negatively impact the clinical course of the disease; patients with longer diagnostic intervals have been shown to experience shorter disease-free survival and higher rates of treatment-related…